Sign in
Active, not recruitingNo phase

Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco

Key facts

Who runs it
Haukeland University Hospital
Where
Norway2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
266 people enrolled
Started
7 Apr 2022
Expected to end
Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Nicotine patch
  • Nicotine gum
  • Nicotine lozenge
  • Smoking cessation counselling
  • Screening for use of tobacco products
  • Screening for interest in smoking cessation
Record updated
28 June 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Receiving OAT from an included outpatient clinic with weekly follow-up
  • Smoking at least one cigarette per day or seven cigarettes per week
  • Obtaining informed consent

Who cannot take part

  • Allergies or prior anaphylactic reactions to medication used
  • Smoking less than three times a week

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background: About 85% of those receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Cigarette smoke lead to lunge diseases and cause illness and death within this group. BAReNikotin is a multicentre randomised controlled clinical trial that will test if integration of smoking cessation therapy to clinical practice at OAT-clinics will increase the rate of OAT-patients that quit smoking.

Read full original descriptionShow less

Intervention: The patients selected for the intervention arm will receive smoking cessation therapy including weekly brief behavioural interventions and prescription-free nicotine replacement products such as nicotine lozenges, patches and chewing gum for at least 16 weeks. This will be compared to a group of patients, who does not receive any help to quit smoking, apart from intial screening of smoking behaviour and advice on where to buy nicotine replacement products.

The patients will have to attend OAT outpatient clinics in Bergen and Stavanger, Norway. The main evaluation will take place 16 weeks after the start of the study.

Study population: The target group will be patients with severe opioid dependence receiving OAT from outpatient clinics in the aforementioned cities who are smoking tobacco daily.

Expected outcome: The primary goal of the study is to see how many of those patients that are offered smoking cessation treatment, that have stopped smoking or reduced the number of cigarettes smoked by at least one half by the end of the intervention. We will also investigate if quitting smoking changes the well-being, physical fitness and quality of life of the participants. If the nicotine replacement therapy is safe and efficacious, it can be considered for further scale-up.

The 2 groups in the trial

  • InterventionTreatment being tested

    Patients will be offered brief weekly behavioural interventions for smoking cessation and prescription-free nicotine replacement products in addidition standard opioid replacement therapy.

    Treatment: Nicotine patch, Nicotine gum, Nicotine lozenge, Smoking cessation counselling, Screening for use of tobacco products, and Screening for interest in smoking cessation

  • Intitial screening onlyOther group

    Participants will receive standard opioid replacement therapy. At the start of the intervention number of cigarettes smoked during the past week will be recorded. Smokers will be adviced to make a cessation or reduction attempt. Advice that nicotine replacement products ( patches, lozenges or gum) may be bought over the counter in grocery-stores and pharmacies and information about goverment home-pages giving cessation advice.

    Treatment: Screening for use of tobacco products and Screening for interest in smoking cessation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Integration of Smoking Cessation Into Standard Treatment for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco: Protocol for a Randomised Controlled Trial
Publications
Record updated
28 June 2024